Comparison of Alternative Tumor Size Classifications for Posterior Uveal Melanomas

Skinner, Cassandra C.; Augsburger, James J.; Augsburger, Bret D.; Corrêa, Zélia M.

doi:10.1167/iovs.16-20465

Cited by 14 publications

(13 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may explain why the prognostic accuracy of LBD alone was similar to the entire clinical TNM staging system in this study and others. 10 Third, the assessment of “T” variables, such as measuring tumor dimensions and determining ciliary body involvement, is not standardized and may vary from center to center. 27,28 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Gene Expression Profiling and PRAME Status Versus Tumor-Node-Metastasis Staging for Prognostication in Uveal Melanoma

Cai

Paez-Escamilla

Walter

et al. 2018

American Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Additionally, the inherent complexity of the TNM methodology limits its precision, reproducibility, and ease of use in the clinical setting. 10,11…”

Section: Introductionmentioning

confidence: 99%

Gene Expression Profiling and PRAME Status Versus Tumor-Node-Metastasis Staging for Prognostication in Uveal Melanoma

Cai

Paez-Escamilla

Walter

et al. 2018

American Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Despite advances in UM therapies, almost half of the patients are ultimately at risk for developing metastatic disease, primarily due to the inability to identify a unique feature of UM which is early micro-metastases [13]. Owing to this frequent subsequent presentation, patients diagnosed with UM require periodic surveillance with physical examination, blood tests and radiographic imaging such as CT, MRI, abdominal ultrasound or PET/CT.…”

Section: Prognosismentioning

confidence: 99%

Clinical management of uveal melanoma: a comprehensive review with a treatment algorithm

et al. 2020

View full text Add to dashboard Cite

Melanoma is a malignancy that originates from the neoplastic proliferation of melanin-producing cells known as melanocytes, which can be primarily found in the skin, ocular region and mucous membranes. Uveal melanoma (UM) is the most frequently occurring non-cutaneous melanoma and is the most common primary intraocular malignancy in adults [1]. The uveal tract, a layer underlying the sclera of the eye, includes the iris, ciliary body and choroid. Around 95% of uveal melanomas arise from the choroidal melanocytes. 1. Epidemiology The worldwide incidence of UM is estimated to be close to 4 to 5 Uveal melanoma (UM), the most frequently occurring non-cutaneous melanoma and most common primary intraocular malignancy in adults, arises from the melanocytes of the choroid in approximately 95% of cases. Prompt diagnosis and treatment is vital as primary tumor size is one of the key factors associated with survival. Despite recent advances in management, more than half of the patients develop metastatic disease which portends poor survival. Currently, treatment options for UM include local resection, enucleation, plaque brachytherapy, and/or particle beam radiotherapy (RT). Enucleation was initially the standard of care in the management of UM, but a shift towards eye-preserving therapeutic choices such as RT and local resection has been noted in recent decades. Plaque brachytherapy, a form of localized RT, is the most popular option and is now the preferred treatment modality for a majority of UM cases. In this review we discuss the etiopathogenesis, clinical presentation and diagnosis of UM and place a special emphasis on its therapeutic options. Furthermore, we review the current literature on UM management and propose a functional treatment algorithm for non-metastatic disease.

show abstract

“…The clinical features incorporated into the 8th edition of the American Joint Committee on Cancer TNM staging system for UM are cumbersome to analyze and include the tumor size, presence or absence of ciliary body involvement and/or extraocular extension, thickness and diameter, lymph node involvement, and presence or absence of metastasis . Ocular oncologists favoring simpler tools for risk assessment in posterior UM consider the 3‐category linear measurement of the tumor's largest basal diameter to be a promising alternative to the unwieldy TNM system . Data generated from applying TNM classification show that the patients at the highest risk for recurrence are those with stage IIIA‐C disease.…”

Section: Challenges In Surveillancementioning

confidence: 99%

Obstacles to improving outcomes in the treatment of uveal melanoma

Tsai

Bollin

Patel

2018

Cancer

View full text Add to dashboard Cite

The rate of advances in uveal melanoma has not kept pace with the rate of advances in cutaneous melanoma. Many patients lack access to or knowledge of specialty centers, and integrated multidisciplinary care between ophthalmology, radiation oncology, and medical oncology is far from the norm. This treatment isolation leads to limited communication about novel clinical trial opportunities. Clinical trials themselves are not widely available, and a lack of robust funding limits rapid and complete investigations. This review outlines the obstacles to success in uveal melanoma management and highlights strategies for overcoming these challenges. Cancer 2018;124:2693-2703. © 2018 American Cancer Society.

show abstract

Comparison of Alternative Tumor Size Classifications for Posterior Uveal Melanomas

Cited by 14 publications

References 17 publications

Gene Expression Profiling and PRAME Status Versus Tumor-Node-Metastasis Staging for Prognostication in Uveal Melanoma

Gene Expression Profiling and PRAME Status Versus Tumor-Node-Metastasis Staging for Prognostication in Uveal Melanoma

Clinical management of uveal melanoma: a comprehensive review with a treatment algorithm

Obstacles to improving outcomes in the treatment of uveal melanoma

Contact Info

Product

Resources

About